Markets
BSE See NSE See 38,310.49
-59.14 (-0.15%)
Investment Conundrums Amidst A Crisis

Investment Conundrums Amidst A Crisis

Print

 

Pravin Bhalerao
Founder and Managing Partner Pranitya Wealth Advisors


The corona virus pandemic hit India in late March 2020, especially at a time when some green shoots were starting to become visible through the first two months of the year. Economic activity had started picking up on the back of single-digit earnings’ growth seen over the past six years. No one got adequate time to assimilate and comprehend the situation.

To read the entire article, you must be a DSIJ magazine subscriber.

 

Comments are only visible to subscribers.

DSIJ Mindshare

Zydus Cadila launches Remdesivir injection at Rs 2,800

Nidhi Jani / Article rating: 4.3

A few other companies have also launched Remdesivir recently, which includes names like Cipla at a price of Rs 4,000 and Jubilant Life Sciences at Rs 4,700. Further, Dr Reddy is also expecting to launch Remdesivir in August 2020 and it has received a voluntary licence from Gilead Sciences to manufacture and distribute the said drug.

12345Last